Loading data for DVA — first visit, this takes a few seconds.

DaVita Inc. (DVA)

NYSE: DVA · Real-Time Price · USD

181.55

+0.22 (0.12%)

At close: Sep 11, 2026, 3:59 PM

181.55

+0.00%

After-hours: 5:05 PM

Alert

The price, the headline numbers and the latest news, in one place.

0.12% (1D)

Bid	174.25
Market Cap	11.6B
Revenue (ttm)	14B
Net Income (ttm)	822M
	0.83
	11.8
	15.39
	10.52
P/B (ttm)	-15.18
P/S (ttm)	0.83
Earnings Date	Oct 28, 2026

Ask	184
Volume	767,844
Avg. Volume (20D)	826,901
Open	181.24
Previous Close	181.33
Day's Range	180.96 - 183.90
52-Week Range	101.00 - 247.49
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About DVA

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory te...

[Read more]

Industry Medical Care Facilities

Sector Healthcare

IPO Date Oct 31, 1995

Employees 78,000

Stock Exchange NYSE

Ticker Symbol DVA

Website https://www.davita.com

Full Company Profile

Financial Performance

In 2025, DaVita's revenue was 13.64B, an increase of 6.46% compared to the previous year's 12.82B. Earnings were 746.8M, a decrease of -20.24%.

Financial Statements

Earnings Surprise

DaVita has released their quarterly earnings on Aug 4, 2026:

Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
EPS of 4.02 exceeds estimates by 0.14, with 36.27% YoY growth.

Next Earnings Release

DaVita Inc. is scheduled to release its earnings on Oct 28, 2026, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 days ago · Zacks

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.

3 days ago · StockStory

3 Reasons to Sell DVA and 1 Stock to Buy Instead

DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the s...

1 week ago · Zacks

Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

1 week ago · StockStory

3 of Wall Street’s Favorite Stocks We Find Risky

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings...

1 week ago · Simply Wall St.

DaVita (DVA) Has Investors Asking A Fresh Question

DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million set...

Page 1 of 2